# Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

> **NCT01475149** · — · COMPLETED · sponsor: **Hospital for Special Surgery, New York** · enrollment: 33 (actual)

## Conditions studied

- Antiphospholipid Syndrome
- Thrombophilia Due to Antiphospholipid Antibody
- Systemic Lupus Erythematosus

## Interventions

- **OTHER:** Phlebotomy

## Key facts

- **NCT ID:** NCT01475149
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-09
- **Final completion:** 2016-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475149, "Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01475149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*